STK Vs. TDVI: The Unicorn CEF And Its Closest ETF EquivalentSeeking Alpha · Oct 12, 2026
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire · Oct 12, 2026
Columbia Seligman Premium Technology Growth Fund Announces a Fourth Quarter Distribution: 9.25% Annual Rate for IPO InvestorsBusiness Wire · Oct 9, 2026
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire · Oct 6, 2026
How To Potentially Retire In Your 40sSeeking Alpha · Oct 3, 2026
STK: This Tech CEF Is Crushing QQQ, And Is Still Trading At A DiscountSeeking Alpha · Aug 20, 2026The Columbia Seligman Premium Technology Growth Fund is a closed-end equity mutual fund, overseen by Columbia Management Investment Advisers, LLC. This U.S.-domiciled fund, established on November 30, 2009, (and formerly known as the Seligman Premium Technology Growth Fund, Inc.) allocates capital to public equity markets. Its core investment strategy involves primarily targeting growth companies within the technology sector.